Basilea Pharmaceutica AG Total Liabilities
Basilea Pharmaceutica AG total liabilities. Based on the latest financial reports, Basilea Pharmaceutica AG (BSLN) has total liabilities worth CHF154.06 Million CHF (≈ $194.77 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BSLN financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Basilea Pharmaceutica AG (2002–2025)
Total liabilities of Basilea Pharmaceutica AG from 2002 to 2025. This chart illustrates how Basilea Pharmaceutica AG's total liabilities have evolved over time, based on quarterly financial data. Explore BSLN long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Basilea Pharmaceutica AG Competitors by Total Liabilities
The table below lists competitors of Basilea Pharmaceutica AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guizhou Guihang Automotive Components Co Ltd
SHG:600523
|
China | CN¥865.89 Million |
|
JSE Limited
JSE:JSE
|
South Africa | ZAC62.48 Billion |
|
Air New Zealand Ltd
AU:AIZ
|
Australia | AU$7.31 Billion |
|
Amsterdam Commodities NV
AS:ACOMO
|
Netherlands | €545.11 Million |
|
Jiangsu Changbao Steeltube Co Ltd
SHE:002478
|
China | CN¥2.73 Billion |
|
Guangdong Xinhui Meida Nylon Co Ltd
SHE:000782
|
China | CN¥2.79 Billion |
|
Ability Opto-Electronics Technology Co Ltd
TWO:3362
|
Taiwan | NT$6.98 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Basilea Pharmaceutica AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Basilea Pharmaceutica AG (BSLN) total assets.
Liquidity & Leverage Metrics
Basilea Pharmaceutica AG Total Liabilities Ratios Explained
Basilea Pharmaceutica AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.25 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Basilea Pharmaceutica AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Basilea Pharmaceutica AG (2002–2025)
The table below shows the annual total liabilities of Basilea Pharmaceutica AG from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF154.06 Million ≈ $194.77 Million |
-12.85% |
| 2024-12-31 | CHF176.76 Million ≈ $223.48 Million |
-3.56% |
| 2023-12-31 | CHF183.29 Million ≈ $231.73 Million |
-24.12% |
| 2022-12-31 | CHF241.56 Million ≈ $305.40 Million |
-21.03% |
| 2021-12-31 | CHF305.87 Million ≈ $386.71 Million |
-7.82% |
| 2020-12-31 | CHF331.84 Million ≈ $419.54 Million |
+5.54% |
| 2019-12-31 | CHF314.43 Million ≈ $397.52 Million |
-9.76% |
| 2018-12-31 | CHF348.44 Million ≈ $440.52 Million |
-11.25% |
| 2017-12-31 | CHF392.61 Million ≈ $496.36 Million |
+8.23% |
| 2016-12-31 | CHF362.76 Million ≈ $458.62 Million |
-5.50% |
| 2015-12-31 | CHF383.88 Million ≈ $485.33 Million |
+92.47% |
| 2014-12-31 | CHF199.45 Million ≈ $252.15 Million |
-12.86% |
| 2013-12-31 | CHF228.88 Million ≈ $289.37 Million |
-15.18% |
| 2012-12-31 | CHF269.84 Million ≈ $341.15 Million |
+221.93% |
| 2011-12-31 | CHF83.82 Million ≈ $105.97 Million |
-21.15% |
| 2010-12-31 | CHF106.30 Million ≈ $134.39 Million |
-2.37% |
| 2009-12-31 | CHF108.88 Million ≈ $137.65 Million |
-15.19% |
| 2008-12-31 | CHF128.38 Million ≈ $162.31 Million |
+1.61% |
| 2007-12-31 | CHF126.34 Million ≈ $159.73 Million |
+39.18% |
| 2006-12-31 | CHF90.78 Million ≈ $114.77 Million |
+3.52% |
| 2005-12-31 | CHF87.69 Million ≈ $110.87 Million |
+314.02% |
| 2004-12-31 | CHF21.18 Million ≈ $26.78 Million |
+26.60% |
| 2003-12-31 | CHF16.73 Million ≈ $21.15 Million |
-33.43% |
| 2002-12-31 | CHF25.13 Million ≈ $31.77 Million |
-- |
About Basilea Pharmaceutica AG
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus au… Read more